BI-D1870 is a small molecule, specific inhibitor of p90 RSK (ribosomal S6 kinase) isoforms RSK1, RSK2, RSK3 and RSK4, both in vitro and in vivo, with IC50s are 31 nM, 24 nM, 18 nM, 15 nM, respectively.

CMK is a RSK2 kinase inhibitor.

FMK is a RSK2 kinase inhibitor.

LJH685 is a selective and potent RSK inhibitor.

LJI308 is a selective and potent RSK inhibitor.

LY-2584702 is an orally available inhibitor of p70S6K signaling; inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes.

M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier.

SC1(Pluripotin) is a sustainer of mES self-renewal and ERK 1 inhibitor

SL 0101-1 is a selective inhibitor of p90 Rsk (ribosomal S6 kinase) (IC50 = 89 nM for Rsk-2).

Eudesmin ((-)-Eudesmin) impairs adipogenic differentiation via inhibition of S6K1 signaling pathway. Eudesmin possesses diverse therapeutic effects, including anti-tumor, anti-inflammatory, and anti-bacterial activities.